Sintilimab Combined With Bevacizumab and Liver Protective Support Therapy in Unresectable Hepatocellular Carcinoma

To evaluate the efficacy and safety of sintilimab combined with bevacizumab and liver protective support therapy in Child-Pugh B and/or ECOG PS 2 unresectable hepatocellular carcinoma

Inclusion Criteria:Advanced unresectable hepatocellular carcinoma confirmed by histology or cytologyAge 20-79At least one measurable lesion defined in RECIST version 1.1Child Pugh grade BECOG PS score 2The expected life is at least 90 daysExclusion Criteria:Previously received anti-PD-1, PD-L1, PD-L2, CD137, CTLA-4 antibody treatment, or any other treatment that regulates T cellsReceived systemic corticosteroid or immunosuppressive therapy within 28 days before enrollmentComplicated with autoimmune diseases or having a history of chronic or recurrent autoimmune diseasesHistory of pleural or pericardial adhesions within 28 days before enrollmentHIV antibody, HTV-Ⅰantibody, HCV antibody, hepatitis B surface protein antigen, hepatitis B surface protein antibody, hepatitis B core protein antibody or any detectable hepatitis B virus DNA test results were positiveMultiple primary cancers (excluding completely resected basal cell carcinoma, stage I squamous cell carcinoma, carcinoma in situ, intramucosal carcinoma, superficial bladder cancer, and any other cancer that has not recurred for at least 5 years)Brain or meningeal metastasis (unless asymptomatic and does not require treatment)Uncontrollable or serious cardiovascular disease.